Hentet fra Phoenix Rising:
“I and a few other colleagues just completed a large conference call with NIH officials and many interested parties regarding the proposed *Lipkin* study which is poised to soon be launched.
Results are expected by early next year or sooner on 150 CFS cases and 150 matched controls from six centers familiar with CFS (Stanford U., Harvard U., U. Miami, NYC, Incline Village and Salt Lake City).These cases are from three academic centers and three private practices who see CFS cases.
The study, independently agreed upon by three XMRV investigators (WPI-Mikovits, FDA-Lo/Alter and CDC-Switzer), and overseen by Ian Lipkin himself at the NIH will resolve the current disagreements on:
a) the existence of detectable XMRV/MLV in CFS
b) the association of XMRV/MLV with CFS.
After listening to about 20 key players on three continents as well as Lipkin himself who appears very non-partisan, there is no doubt in my mind what this study will show with the full backing of the NIH in its outcome and conclusions.
The good thing will be that all reagents will be certified as contaminant free.
All samples will be collected the same way and cases/controls assessed the same way.
In the analysis, though different labs will do *their thing*, they are allowed the methods they choose.
If a sample is positive from any of the three, it will be counted positive and if any sample is negative from all three, it will be counted as negative.
If one sample is positive from one site and negative from the other two, it will be deemed positive for purposes of the study conclusions.
Judy Mikovits will employ four different assays (culture, PCR, western blot with sequencing and serology) while Alter/Lo will employ PCR on plasma and Switzer will use PCR on extracted DNA as sole tests.
May the games begin and the best man or woman win.
If Judy Mikovits can, in a blinded fashion, come to the same conclusions she arrived at before in the Science paper, the sky will fall in on all other naysayers and reputations and egos will suffer great humiliation.
I am confident she will do well and so is she.
If not, the patients are no worse off than before and this disease will remain the enigma it has always been to those who treat it and those who live it.
However, I would not want to be Switzer or the CDC or Jay Levy or Singh or John Coffin or the Science editors or most of the UK medical establishment right now.
The odds are not in their favor but we will see. I think they are all on the Titanic after what I heard today.”
Les mer HER
Les på norsk med Google Translater HER